MucoLife Therapeutics secures €91K from Vinnova to scale COPD peptide synthesis
The Swedish innovation agency funded preclinical manufacturing scale-up for an inhaled peptide targeting airway mucus plugs.
Swedish startup MucoLife Therapeutics has received a grant of €91,000 (1 million Swedish kronor) from Sweden’s innovation agency Vinnova, Tech.eu reported tech.eu
Tech.eutech.euOpen source ↗. The financing was allocated under the program supporting small and medium-sized enterprises in utilizing life science infrastructure.
Targeted airway therapy
The funding will support the establishment of a scalable production process for MLT-001, a preclinical inhaled peptide. The molecule is designed to directly dissolve airway mucus plugs in chronic obstructive pulmonary disease (COPD). According to clinical statistics cited by the developers, mucus plugging affects more than half of patients with moderate-to-severe forms of the disease, while no approved direct therapies currently exist. Such airway obstructions correlate with accelerated declines in lung function, frequent exacerbations, and higher mortality rates.
Preparations for GMP production
Preliminary work confirmed that the chemical synthesis of MLT-001 is technically scalable. The team will conduct the engineering scale-up alongside an unnamed contract development and manufacturing organization (CDMO) partner.
The technical collaboration aims to achieve high purity levels alongside documented yield metrics, as well as compile a transferable process description tech.eu
Tech.eutech.euOpen source ↗. According to chief executive officer Thaher Pelaseyed, developing this purification and control strategy serves as the foundation for future Good Manufacturing Practice (GMP) operations ahead of clinical trials.
